Lowest Price Guaranteed From USD 2,499
Published
September 2017
Pages
346
View Count
5211
Example Insights
An updated edition is available at the following link
Report Description
A number of monoclonal antibodies (more than 70) have already been approved for use in humans. These therapeutic products, which target a particular epitope on an antigen, have become a popular and robust treatment option for various diseases. However, despite the success of antibody therapeutics, there are several limitations associated with the use of mono-specific antibodies. It has been reported that certain patients treated using these therapeutic modalities have failed to respond, or have developed resistance to the therapy. Moreover, since the development and progression of several diseases, such as cancer, are dependent on the cross-talk between multiple signaling pathways, molecules directed against a single target may not elicit the desired therapeutic effect.
Bispecific antibodies have demonstrated the capability to address the existing challenges associated with monoclonal antibodies, such as high manufacturing costs, limited applicability in assays and the general lack of understanding of precise in vivo mechanisms of action. Although the concept of bispecific antibodies was conceived more than five decades ago, this field has gained significant popularity in recent years. These molecules have the potential to be used across a broad range of application areas; for example, they can be used to redirect effector cells, simultaneously modulate more than one signaling pathway, and deliver toxic payloads to target sites in a more specific manner. It is also important to highlight that advances in molecular cloning technologies, coupled with a better understanding of antibody engineering techniques, have led to the discovery and development of a number of different bispecific antibody formats, setting them up for use across novel application areas as well.
Scope of the Report
The ‘Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030’ report provides a comprehensive study of the current landscape of bispecific antibodies, featuring an elaborate discussion on the future potential of this upcoming market. The field has captured the interest of several drug developers, including both small and large companies. As indicated before, the applicability of these engineered biomolecules is vast. Presently, only one bispecific antibody, BLINCYTO® (2014), is available for therapeutic use. However, the development pipeline of bispecific antibody based drugs has several promising candidates that are likely to result in commercial success stories in the foreseen future. The overall pipeline comprises of over 200 molecules that are under development for the treatment of various disease indications across different therapeutic areas, including oncology, autoimmune disorders and infectious diseases. Of these, more than 60 molecules are currently under clinical evaluation, while over 140 product candidates are in the discovery / preclinical stages.
The evolving market has its hopes pinned on multiple start-ups, small and large-sized companies, which are engaged in this domain. Amongst other elements, the report features:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2017-2030. The research, analysis and insights presented in this report include potential sales of bispecific antibody therapeutics that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of novel bispecific antibody therapeutics and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Jane Dancer (CBO, F-star), Siobhan Pomeroy (Senior Director, Business Development, CytomX Therapeutics), Ludge Große-Hovest (Founder and CSO, Synimmune) and Yinjue Wang (Associate Director, Process Development, Innovent Biologics). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high level view on the likely evolution of the bispecific antibody therapeutics market in the mid to long term.
Chapter 3 provides a general overview of antibodies covering their historical background, structure, and the types of antibodies available, along with their mechanisms of action. In addition, the chapter highlights the evolution of antibody based therapeutics over the last few years. It also features a discussion on bispecific antibodies, elaborating on the different bispecific formats that are currently available, mechanisms of action of various products / product candidates and their applications.
Chapter 4 includes information on over 200 bispecific antibody therapeutics that are currently in different stages of development. It features a comprehensive analysis of the pipeline molecules, highlighting the target therapeutic areas, phases of development, antibody formats, routes of administration and the corresponding mechanisms of action.
Chapter 5 provides a list of technologies that are either currently available, or being developed by various firms, for the generation of bispecific antibody therapeutics. In addition, it features detailed profiles of some of the key technologies that have been used to develop at least four clinical and / or preclinical bispecific antibody candidates. Each profile contains details on the technology, such as the structure of bispecific antibody, pipeline molecules developed using the technology, its advantages and partnerships established related to the technology.
Chapter 6 contains detailed profiles of drugs that are in advanced stages of clinical development (phase II, filed and marketed). Each profile provides information on the mechanism of action, current status of development, dosage form and treatment regimen, information on clinical studies and key clinical trial results of the drug. It also includes an overview of the developer, its financial details and an informed future outlook.
Chapter 7 presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It includes future sales projections of bispecific antibody therapeutics that are either marketed or are in advanced stages of clinical development (phase II and preregistration). The sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of key therapeutic areas (oncology, autoimmune disorders, inflammatory disorders, eye disorders and others) and mechanisms of action (T-cell engagement, NK-cell engagement, dual targeting, blocking cytokines and others).
Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models and the most common forms of deals / agreements that have been established between 2012 and 2017.
Chapter 9 is a compilation of key insights derived from the study. It presents a detailed logo landscape of the companies engaged in developing bispecific antibody based products, distributed based on the developmental status of pipeline candidates and size of the companies (small, mid-sized and large companies). The chapter also features a grid analysis, representing the distribution of bispecific antibody candidates (on the basis of their mechanisms of action and formats) across target therapeutic areas and stages of development. It also features a comparative study, presented in the form of a bubble analysis, of the different platforms that are being utilized for the generation of bispecific antibodies. The parameters considered for this analysis include the development activity based on the technology (in terms of the number of drugs across different phases of development), number of partnerships established related to the technology and the size of the developer company. Additionally, the chapter features a spider-web analysis, which highlights the activity of bispecific antibodies based on their mechanisms of action. The parameters considered for this analysis include number of drug candidates, active clinical trials, publications, target indications and the companies that are involved in this domain.
Chapter 10 includes a detailed discussion on product life cycle management strategies. It primarily focuses on the indication expansion strategy, which is being used extensively by the developers of bispecific antibody based therapeutics.
Chapter 11 highlights the key promotional strategies that are being implemented by the developer (Amgen) of the marketed bispecific antibody, BLINCYTO® (approved for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia). For the purpose of this analysis, we also studied the promotional activities of two other drugs, namely Iclusig® and Marqibo®, which are approved for the treatment of the same indication. The promotional aspects covered in the chapter include details provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content, and product visibility in scientific conferences.
Chapter 12 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the bispecific antibodies market within the biopharmaceutical industry, under a comprehensive SWOT framework.
Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 14 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Jane Dancer (CBO, F-star), Siobhan Pomeroy (Senior Director, Business Development, CytomX Therapeutics), Ludge Große-Hovest (Founder and CSO, Synimmune) and Yinjue Wang (Associate Director, Process Development, Innovent Biologics).
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. The Concept of Antibody
3.3. The Structure of Antibody
3.4. Mechanism of Action of Antibody
3.5. Monoclonal Antibodies
3.6. Antibody Therapeutics: A Lucrative Market
3.7. Evolution of Antibody Based Therapeutics
3.7.1. Fc Engineering and Glycoengineering of Therapeutic Antibodies
3.7.2. Antibody Fragments
3.7.3. Fusion with Effector Proteins
3.7.4. Intrabodies
3.7.5. Bispecific Antibodies
3.8. Bispecific Antibodies: Formats
3.8.1. Single-Chain-based formats (Fc Independent Antibody Formats)
3.8.1.1. Tandem scFvs and Triplebodies
3.8.1.2. Bispecific Single-Domain Antibody Fusion Proteins
3.8.1.3. Diabodies or Diabody Derivatives
3.8.1.4. Fab Fusion Proteins
3.8.1.5. Other Fc Region-less Fusion Proteins
3.8.2. Immunoglobulin G-Based Formats (Fc Dependent Antibody Formats)
3.8.2.1. Quadromas
3.8.2.2. Knobs-Into-Holes
3.8.2.3. Dual Variable Domain Immunoglobulin (DVD-Ig)
3.8.2.4. IgG-single chain Fv (scFv)
3.8.2.5. Two-in-One or Dual Action Fab (DAF) Antibodies
3.8.2.6. Half Molecule Exchange
3.8.2.7. κλ- Bodies
3.9. Bispecific Antibodies: Mechanisms of Action
3.9.1. Redirecting Immune Effector Cells towards Tumor Cells
3.9.2. Dual Targeting (Directly Targeting Malignant Cells)
3.9.3. Extending Half-Life
3.9.4. Delivering Cytotoxic Entities to Malignant Cells
3.9.5. Targeting tumor Angiogenesis
3.9.6. Other Mechanisms
3.10. Bispecific Antibodies: Applications
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Bispecific Antibody Therapeutics: Marketed / Clinical Pipeline
4.3. Bispecific Antibody Therapeutics: Preclinical Pipeline
4.4. Bispecific Antibody Therapeutics: Distribution by Phase of Development
4.5. Bispecific Antibody Therapeutics: Distribution by Therapeutic Area
4.6. Bispecific Antibody Therapeutics: Distribution by Mechanism of Action
4.7. Bispecific Antibody Therapeutics: Distribution by Route of Administration
4.8. Bispecific Antibody Therapeutics: Distribution by Type of Format
4.9. Bispecific Antibody Therapeutics: Distribution by Key Players
5. BISPECIFIC ANTIBODY THERAPEUTICS: TECHNOLOGY PLATFORMS
5.1. Chapter Overview
5.2. Bispecific Antibody Therapeutics: List of Technology Platforms
5.3. Bispecific Antibody Therapeutics: Technology Profiles
5.3.1. Biclonics®, Merus
5.3.1.1. Overview
5.3.1.2. Technology Details
5.3.1.3. Structure of Biclonics® Bispecific Antibodies
5.3.1.4. Pipeline of Biclonics® Bispecific Antibodies
5.3.1.5. Advantages of Biclonics® Bispecific Antibodies
5.3.1.6. Collaborations and Partnerships
5.3.2. Bispecific T-cell Engager (BiTE®), Amgen
5.3.2.1. Overview
5.3.2.2. Technology Details
5.3.2.3. Structure of BiTE® Bispecific Antibodies
5.3.2.4. Pipeline of BiTE® Bispecific Antibodies
5.3.2.5. Advantages of BiTE® Bispecific Antibodies
5.3.2.6. Collaborations and Partnerships
5.3.3. Dual-Affinity Re-Targeting (DART®), MacroGenics
5.3.3.1. Overview
5.3.3.2. Technology Details
5.3.3.3. Structure of DART® Bispecific Antibodies
5.3.3.4. Pipeline of DART® Bispecific Antibodies
5.3.3.5. Advantages of DART® Bispecific Antibodies
5.3.3.6. Collaborations and Partnerships
5.3.4. Modular Antibody Technology™, F-star
5.3.4.1. Overview
5.3.4.2. Technology Details
5.3.4.3. Structure of Modular Antibody Technology™ based Bispecific Antibodies
5.3.4.4. Pipeline of Modular Antibody Technology™ based Bispecific Antibodies
5.3.4.5. Advantages of Modular Antibody Technology™ based Bispecific Antibodies
5.3.4.6. Collaborations and Partnerships
5.3.5. TandAb®, Affimed
5.3.5.1. Overview
5.3.5.2. Technology Details
5.3.5.3. Structure of TandAb® Bispecific Antibodies
5.3.5.4. Pipeline of TandAb® Bispecific Antibodies
5.3.5.5. Advantages of TandAb® Bispecific Antibodies
5.3.5.6. Collaborations and Partnerships
5.3.6. ADAPTIR™, Aptevo Therapeutics
5.3.7. CrossMAb Technology, Roche
5.3.8. DuoBody®, Genmab
5.3.9. Nanobody®, Ablynx
5.3.10. XmAb™ Antibody Engineering Platform, Xencor
6. DRUG PROFILES
6.1. Chapter Overview
6.2. BLINCYTO® / Blinatumomab (Amgen)
6.2.1. Overview
6.2.2. Mechanism of Action
6.2.3. Current Status of Development
6.2.4. Clinical Trials
6.2.5. Clinical Findings
6.2.6. Annual Sales
6.2.7. Amgen
6.2.7.1. Overview
6.2.7.2. Financial Information
6.2.7.3. Future Outlook
6.3. Emicizumab / RG6013 (Chugai Pharmaceutical / Roche)
6.3.1. Overview
6.3.2. Mechanism of Action
6.3.3. Current Status of Development
6.3.4. Clinical Trials
6.3.5. Clinical Findings
6.3.6. Chugai Pharmaceutical
6.3.6.1. Overview
6.3.6.2. Financial Information
6.3.6.3. Future Outlook
6.4. ABT-981 (AbbVie)
6.4.1. Overview
6.4.2. Mechanism of Action
6.4.3. Current Status of Development
6.4.4. Clinical Trials
6.4.5. Clinical Findings
6.4.6. AbbVie
6.4.6.1. Overview
6.4.6.2. Financial Information
6.4.6.3. Future Outlook
6.5. Ozoralizumab / ATN103 (Ablynx, Eddingpharm, Taisho Pharmaceutical)
6.5.1. Overview
6.5.2. Mechanism of Action
6.5.3. Current Status of Development
6.5.4. Clinical Trials
6.5.5. Clinical Findings
6.5.6. Ablynx
6.5.6.1. Overview
6.5.6.2. Financial Information
6.5.6.3. Future Outlook
6.6. AFM13 (Affimed)
6.6.1. Overview
6.6.2. Mechanism of Action
6.6.3. Current Status of Development
6.6.4. Clinical Trials
6.6.5. Clinical Findings
6.6.6. Affimed
6.6.6.1. Overview
6.6.6.2. Financial Information
6.6.6.3. Future Outlook
6.7. Istiratumab / MM-141 (Merrimack Pharmaceuticals)
6.7.1. Overview
6.7.2. Mechanism of Action
6.7.3. Current Status of Development
6.7.4. Clinical Trials
6.7.5. Clinical Findings
6.7.6. Merrimack Pharmaceuticals
6.7.6.1. Overview
6.7.6.2. Financial Information
6.7.6.3. Future Outlook
6.8. MEDI3902 (MedImmune /AstraZeneca)
6.8.1. Overview
6.8.2. Mechanism of Action
6.8.3. Current Status of Development
6.8.4. Clinical Trials
6.8.5. AstraZeneca
6.8.5.1. Overview
6.8.5.2. Financial Information
6.8.5.3. Future Outlook
6.9. RG7716 / RO6867461 (Roche / Genentech)
6.9.1. Overview
6.9.2. Mechanism of Action
6.9.3. Current Status of Development
6.9.4. Clinical Trials
6.9.5. Clinical Findings
6.9.6. Roche
6.9.6.1. Overview
6.9.6.2. Financial Information
6.9.6.3. Future Outlook
6.10. SAR156597 (Sanofi)
6.10.1. Overview
6.10.2. Mechanism of Action
6.10.3. Current Status of Development
6.10.4. Clinical Trials
6.10.5. Sanofi
6.10.5.1. Overview
6.10.5.2. Financial Information
6.10.5.3. Future Outlook
6.11. Vobarilizumab, ALX-0061 (Ablynx)
6.11.1. Overview
6.11.2. Mechanism of Action
6.11.3. Current Status of Development
6.11.4. Clinical Trials
6.11.5. Clinical Findings
6.11.6. Ablynx
6.11.6.1. Overview
6.11.6.2. Financial Information
6.11.6.3. Future Outlook
7. MARKET FORECAST AND OPPORTUNITY ANALYSIS
7.1. Chapter Overview
7.2. Scope and Limitations
7.3. Forecast Methodology
7.4. Overall Bispecific Antibody Therapeutics Market
7.5. Bispecific Antibody Therapeutics Market: Individual Drug Forecasts
7.5.1. BLINCYTO® (Amgen)
7.5.1.1. Target Patient Population
7.5.1.2. Sales Forecast
7.5.2. AFM13 (Affimed)
7.5.2.1. Target Patient Population
7.5.2.2. Sales Forecast
7.5.3. Istiratumab (Merrimack Pharmaceuticals)
7.5.3.1. Target Patient Population
7.5.3.2. Sales Forecast
7.5.4. Emicizumab (Chugai Pharmaceutical)
7.5.4.1. Target Patient Population
7.5.4.2. Sales Forecast
7.5.5. ABT-981 (AbbVie)
7.5.5.1. Target Patient Population
7.5.5.2. Sales Forecast
7.5.6. Vobarilizumab (Ablynx)
7.5.6.1. Target Patient Population
7.5.6.2. Sales Forecast
7.5.7. MEDI3902 (AbbVie)
7.5.7.1. Target Patient Population
7.5.7.2. Sales Forecast
7.5.8. RG7716 (Roche)
7.5.8.1. Target Patient Population
7.5.8.2. Sales Forecast
7.5.9. SAR156597 (Sanofi)
7.5.9.1. Target Patient Population
7.5.9.2. Sales Forecast
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Bispecific Antibody Therapeutics: List of Partnerships
8.4. Bispecific Antibody Therapeutics: Partnership Analysis
8.4.1. Analysis by Year of Partnerships
8.4.2. Analysis by Type of Partnership
8.4.3. Analysis by Type of Therapeutic Area
8.4.4. Most Active Companies: Analysis by Number of Partnership
9. KEY INSIGHTS
9.1. Chapter Overview
9.2. Bispecific Antibodies Pipeline: Developer Landscape
9.3. Bispecific Antibodies Pipeline: Therapeutic Area Analysis
9.4. Bispecific Antibody Generation Platforms: Comparative Analysis
9.5. Bispecific Antibody Therapeutics: Spider-Web Analysis
10. CASE STUDY: LIFE CYCLE MANAGEMENT STRATEGIES
10.1. Chapter Overview
10.2. Life Cycle Management Strategies
10.3. Indication Expansion Strategy
11. CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES
11.1. Chapter Overview
11.2. Different Channels of Promotional Campaigns
11.3. Summary: Product Website Analysis
11.4. Summary: Patient Support Services and Informative Downloads
11.5. Summary: Presence in conferences
11.6. BLINCYTO®: Promotional / Marketing Strategy
11.6.1. Drug Overview
11.6.2. Product Website Analysis
11.6.2.1. Messages for Healthcare Professionals
11.6.3. Patient Support Services and Informative Downloads
11.6.4. Presence in Conferences
11.7. Iclusig®: Promotional / Marketing Strategy
11.7.1. Drug Overview
11.7.2. Product Website Analysis
11.7.2.1. Messages for Patients
11.7.2.2. Messages for Healthcare Professionals
11.7.3. Patient Support Services and Informative Downloads
11.7.4. Presence in Conferences
11.8. Marqibo®: Promotional Analysis
11.8.1. Drug Overview
11.8.2. Product Website analysis
11.8.2.1. Messages for Patients
11.8.2.2. Messages for Healthcare Professionals
11.8.3. Patient Support Services and Informative Downloads
11.8.4. Presence in Conferences
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weakness
12.4. Opportunities
12.5. Threats
13. CONCLUSION
13.1. With Multiple Late-phase Candidates, The Bispecific Antibody Therapeutics Market is Characterized by a Robust and Promising Pipeline
13.2. Product Candidates are Being Developed to Treat a Number of Clinical Conditions, With the Primary Focus Being on Oncology
13.3. The Current Market Features an Even Mix of Small-sized, Mid-sized and Large-sized Companies
13.4. Extensive R&D Efforts in this Domain have Led to the Development of Innovative Platform Technologies
13.5. Several Stakeholders have Entered into Strategic Alliances to Further R&D and Product Development Efforts
13.6. Post the Approval and Launch of Multiple Late-Phase Product Candidates, the Market is Expected to Grow at a Rapid Pace
13.7. Concluding Remarks
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Siobhan Pomeroy, Senior Director, Business Development, CytomX Therapeutics
14.3. Jane Dancer, Chief Business Officer O, F-star
14.4. Yinjue Wang, Associate Director, Process development, Innovent Biologics
14.5. Ludger Große-Hovest, Chief Scientific Officer, Synimmune
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Antibody: Key Historic Events
Figure 3.2 Basic Structure of an Antibody
Figure 3.3 Mechanisms of Action of Antibodies
Figure 3.4 Revenues of the Top 15 Drugs, 2016 (USD Billion)
Figure 3.5 Structure: Symmetric and Asymmetric Bispecific Antibodies
Figure 4.1 Bispecific Antibody Therapeutics: Distribution by Phase of Development
Figure 4.2 Bispecific Antibody Therapeutics: Distribution by Therapeutic Area
Figure 4.3 Bispecific Antibody Therapeutics: Distribution by Mechanism of Action
Figure 4.4 Bispecific Antibody Therapeutics: Distribution by Route of Administration
Figure 4.5 Bispecific Antibody Therapeutics: Distribution by Type of Format
Figure 4.6 Bispecific Antibody Therapeutics: Distribution by Key Players
Figure 5.1 Biclonics® Bispecific Antibody: Structure
Figure 5.2 BiTE® Bispecific Antibody: Structure
Figure 5.3 DART® Bispecific Antibody: Structure
Figure 5.4 Modular Antibody Technology™ Bispecific Antibody: Structure
Figure 5.5 TandAb® Bispecific Antibody: Structure
Figure 5.6 ADAPTIR™ Bispecific Antibody: Structure
Figure 5.7 CrossMAb Bispecific Antibody: Structure
Figure 5.8 DuoBody® Bispecific Antibody: Structure
Figure 5.9 Nanobody® Bispecific Antibody: Structure
Figure 6.1 BLINCYTO®: Annual Sales, 2015-H1 2017 (USD Million)
Figure 6.2 Amgen: Annual Revenues, 2012-H1 2017 (USD Billion)
Figure 6.3 Chugai Pharmaceutical: Annual Revenues, 2012-Q1 2017 (JPY Billion)
Figure 6.4 AbbVie: Annual Revenues, 2012-H1 2017 (USD Billion)
Figure 6.5 Ablynx: Annual Revenues, 2012-H1 2017 (EUR Million)
Figure 6.6 Affimed: Annual Revenues, 2012- H1 2017 (EUR Million)
Figure 6.7 Merrimack Pharmaceuticals: Annual Revenues, 2012-H1 2017 (USD Million)
Figure 6.8 AstraZeneca: Annual Revenues, 2012-H1 2017 (USD Billion)
Figure 6.9 Roche: Annual Revenues, 2012-H1 2017 (CHF Billion)
Figure 6.10 Sanofi: Annual Revenues, 2012-H1 2017 (EUR Billion)
Figure 7.1 Overall Bispecific Antibody Therapeutics Market, 2017-2030: Base Scenario (USD Billion)
Figure 7.2 Bispecific Antibody Therapeutics Market (USD Billion), 2017, 2023 and 2030 (Base Scenario): Distribution by Therapeutic Area
Figure 7.3 Bispecific Antibody Therapeutics Market (USD Billion), 2017, 2023 and 2030 (Base Scenario): Distribution by Mechanism of Action
Figure 7.4 Bispecific Antibody Therapeutics Market (USD Billion), 2017, 2023 and 2030 (Base Scenario): Distribution by Drugs
Figure 7.5 BLINCYTO® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 7.6 AFM13 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 7.7 Istiratumab Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 7.8 Emicizumab Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 7.9 ABT-981 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 7.10 Vobarilizumab Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 7.11 MEDI3902 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 7.12 RG7716 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 7.13 SAR156597 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 8.1 Bispecific Antibody Therapeutics Partnerships: Cumulative Trend by Year (2012–2017)
Figure 8.2 Bispecific Antibody Therapeutics Partnerships: Distribution by Type of Partnership
Figure 8.3 Bispecific Antibody Therapeutics Partnerships: Distribution by Type of Therapeutic Area
Figure 8.4 Bispecific Antibody Therapeutics Partnerships: Most Active Companies
Figure 9.1 Bispecific Antibody Therapeutics Market: Developer Landscape
Figure 9.2 Bispecific Antibody Therapeutics Clinical Pipeline: Therapeutic Area Analysis
Figure 9.3 Bispecific Antibody Therapeutics Early Stage Pipeline: Therapeutic Area Analysis
Figure 9.4 Bispecific Antibodies Generation Platforms: 3-Dimensional Comparative Analysis
Figure 9.5 Bispecific Antibody Mechanisms of Action: 5-Dimensional Spider-Web Analysis
Figure 10.1 Bispecific Antibody Therapeutics: LCM Strategy Heat Map Analysis
Figure 10.2 Bispecific Antibody Therapeutics: LCM Strategy (Indication Expansion)
Figure 11.1 Promotional / Marketing Strategy: Product Website Analysis
Figure 11.2 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Figure 11.3 Promotional / Marketing Strategy: Presence in Conferences
Figure 11.4 BLINCYTO®: Product Website Analysis (Messages for Healthcare Professionals)
Figure 11.5 BLINCYTO®: Amgen Assist 360 Nurse Ambassador
Figure 11.6 BLINCYTO®: Presence in Conferences
Figure 11.7 Iclusig®: Product Website Analysis (Messages for Patients)
Figure 11.8 Iclusig®: Product Website Analysis (Messages for Healthcare Professionals)
Figure 11.9 Iclusig®: Point Program
Figure 11.10 Iclusig®: Presence in Conferences
Figure 11.11 Marqibo®: Product Website Analysis (Messages for Patients)
Figure 11.12 Marqibo®: Product Website Analysis (Messages for Healthcare Professionals)
Figure 11.13 Marqibo®: STAR Program
Figure 11.14 Marqibo®: Presence in Conferences
Figure 13.1 Bispecific Antibody Therapeutics Market, 2017, 2023, and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 3.1 Mechanisms of Action of Therapeutic Antibodies Against Different Target Classes
Table 3.2 Top Ten Therapeutic Antibodies 2016
Table 4.1 Bispecific Antibody Therapeutics: Marketed / Clinical Pipeline
Table 4.2 Bispecific Antibody Therapeutics: Preclinical Pipeline
Table 5.1 Bispecific Antibody Therapeutics: List of Technology Platforms
Table 5.2 Biclonics® Bispecific Antibodies: Development Pipeline
Table 5.3 BiTE® Bispecific Antibodies: Development Pipeline
Table 5.4 DART® Bispecific Antibodies: Development Pipeline
Table 5.5 Modular Antibody Technology™ based Bispecific Antibodies: Development Pipeline
Table 5.6 TandAb® Bispecific Antibodies: Development Pipeline
Table 5.7 ADAPTIR™ Bispecific Antibodies: Development Pipeline
Table 5.8 CrossMAb Bispecific Antibodies: Development Pipeline
Table 5.9 DuoBody® Bispecific Antibodies: Development Pipeline
Table 5.10 Nanobody® Bispecific Antibodies: Development Pipeline
Table 5.11 XmAb™ Bispecific Antibodies: Development Pipeline
Table 6.1 Bispecific Antibody Therapeutics: Approved / Late-Stage Molecules
Table 6.2 BLINCYTO®: Current Status of Development
Table 6.3 BLINCYTO®: Clinical Trials
Table 6.4 BLINCYTO®: Results of the (TOWER Study)
Table 6.5 BLINCYTO®: Efficacy Results (ALCANTARA Study)
Table 6.6 Amgen: Bispecific Antibody Product Portfolio
Table 6.7 Emicizumab: Current Status of Development
Table 6.8 Emicizumab: Clinical Trials
Table 6.9 Emicizumab: Design of Phase I Trial (ACE001JP)
Table 6.10 Emicizumab: Mean Annualized Bleeding Rate in Phase I Trial (ACE001JP)
Table 6.11 Emicizumab Phase I/II: Mean Annualized Bleeding Rate / Annualized Joint Bleeding Rate in Phase I/II Trial
Table 6.12 ABT-981: Current Status of Development
Table 6.13 ABT-981: Clinical Trials
Table 6.14 AbbVie: Bispecific Antibody Product Portfolio
Table 6.15 Ozoralizumab: Current Status of Development
Table 6.16 Ozoralizumab: Clinical Trials
Table 6.17 Ozoralizumab: ACR20, ACR50 and ACR70 in Phase II Trial (NCT01063803)
Table 6.18 Ozoralizumab: Safety Results of Phase II Trial (NCT01063803)
Table 6.19 Ablynx: Bispecific Antibody Product Portfolio
Table 6.20 AFM13: Current Status of Development
Table 6.21 AFM13: Clinical Trials
Table 6.22 Affimed: Bispecific Antibody Product Portfolio
Table 6.23 MM-141: Current Status of Development
Table 6.24 MM-141: Clinical Trials
Table 6.25 MEDI3902: Current Status of Development
Table 6.26 MEDI3902: Clinical Trials
Table 6.27 RG7716: Current Status of Development
Table 6.28 RG-7716: Clinical Trials
Table 6.29 Roche: Bispecific Antibody Product Portfolio
Table 6.30 SAR156597: Current Status of Development
Table 6.31 SAR156597: Clinical Trials
Table 6.32 Vobarilizumab: Current Status of Development
Table 6.33 Vobarilizumab: Clinical Trials
Table 6.34 Vobarilizumab Monotherapy: Results of the Phase II Study
Table 6.35 Vobarilizumab Monotherapy: Safety Results
Table 7.1 Bispecific Antibody Therapeutics: Expected Launch Years of Advanced Stage Drug Candidates
Table 7.2 BLINCYTO®: Target Patient Population
Table 7.3 AFM13: Target Patient Population
Table 7.4 Istiratumab: Target Patient Population
Table 7.5 Emicizumab: Target Patient Population
Table 7.6 ABT-981: Target Patient Population
Table 7.7 Vobarilizumab: Target Patient Population
Table 7.8 MEDI3902: Target Patient Population
Table 7.9 RG7716: Target Patient Population
Table 7.10 SAR156597: Target Patient Population
Table 8.1 Bispecific Antibody Therapeutics: Recent Partnerships
Table 9.1 Bispecific Antibody Therapeutics: Spider-Web Analysis
Table 11.1 BLINCYTO®: Drug Overview
Table 11.2 Iclusig®: Drug Overview
Table 11.3 Marqibo®: Drug Overview
Table 12.1 Bispecific Antibody Therapeutics: SWOT Analysis
Table 12.2 Bispecific Antibody Therapeutics: Contract Manufacturing Organizations
Table 15.1 Revenues of the Top 15 Drugs, 2016 (USD Billion)
Table 15.2 Bispecific Antibody Therapeutics: Distribution by Phase of Development
Table 15.3 Bispecific Antibody Therapeutics: Distribution by Therapeutic Area
Table 15.4 Bispecific Antibody Therapeutics: Distribution by Mechanism of Action
Table 15.5 Bispecific Antibody Therapeutics: Distribution by Route of Administration
Table 15.6 Bispecific Antibody Therapeutics: Distribution by Type of Format
Table 15.7 Bispecific Antibody Therapeutics: Distribution by Key Players
Table 15.8 BLINCYTO®: Annual Sales, 2015-H1 2017 (USD Million)
Table 15.9 Amgen: Annual Revenues, 2012-H1 2017 (USD Billion)
Table 15.10 Chugai Pharmaceutical: Annual Revenues, 2012-H1 2017 (JPY Billion)
Table 15.11 AbbVie: Annual Revenues, 2012-H1 2017 (USD Billion)
Table 15.12 Ablynx: Annual Revenues, 2012-H1 2017 (EUR Million)
Table 15.13 Affimed Therapeutics: Annual Revenues, 2012- H1 2017 (EUR Million)
Table 15.14 Merrimack Pharmaceuticals: Annual Revenues, 2012-H1 2017 (USD Million)
Table 15.15 AstraZeneca: Annual Revenues, 2012-H1 2017 (USD Billion)
Table 15.16 Roche: Annual Revenues, 2012-H1 2017 (CHF Billion)
Table 15.17 Sanofi: Annual Revenues, 2012-H1 2017 (EUR Billion)
Table 15.18 Overall Bispecific Antibody Therapeutics Market, 2017-2030: Base Scenario (USD Billion)
Table 15.19 Overall Bispecific Antibody Therapeutics Market, 2017-2030: Optimistic Scenario (USD Billion)
Table 15.20 Overall Bispecific Antibody Therapeutics Market, 2017-2030: Conservative Scenario (USD Billion)
Table 15.21 Bispecific Antibody Therapeutics Market (USD Million), 2017, 2023 and 2030 (Base Scenario): Distribution by Therapeutic Area
Table 15.22 Bispecific Antibody Therapeutics Market (USD Million), 2017, 2023 and 2030 (Base Scenario): Distribution by Mechanism of Action
Table 15.23 Bispecific Antibody Therapeutics Market (USD Million), 2017, 2023 and 2030 (Base Scenario): Distribution by Drugs
Table 15.24 BLINCYTO® Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 15.25 BLINCYTO® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 15.26 BLINCYTO® Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 15.27 AFM13 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 15.28 AFM13 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 15.29 AFM13 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 15.30 Istiratumab Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 15.31 Istiratumab Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 15.32 Istiratumab Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 15.33 Emicizumab Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 15.34 Emicizumab Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 15.35 Emicizumab Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 15.36 ABT-981 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 15.37 ABT-981 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 15.38 ABT-981 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 15.39 Vobarilizumab Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 15.40 Vobarilizumab Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 15.41 Vobarilizumab Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 15.42 MEDI3902 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 15.43 MEDI3902 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 15.44 MEDI3902 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 15.45 RG7716 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 15.46 RG7716 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 15.47 RG7716 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 15.48 SAR156597 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 15.49 SAR156597 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 15.50 SAR156597 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 15.51 Bispecific Antibody Therapeutics Partnerships: Cumulative Trend by Year (2012–2017)
Table 15.52 Bispecific Antibody Therapeutics Partnerships: Distribution by Type of Partnership
Table 15.53 Bispecific Antibody Therapeutics Partnerships: Distribution by Type of Therapeutic Area
Table 15.54 Bispecific Antibody Therapeutics Partnerships: Most Active Companies
Table 15.55 Summary: Presence in Conferences
Table 15.56 Bispecific Antibody Therapeutics Market (USD Billion), 2017, 2023 and 2030
The following companies and organizations have been mentioned in the report.